InMed Files PCT Patent For Rare Cannabinoid Treatment

A company focused on manufacturing, developing, and commercializing rare cannabinoids has filed a patent application demonstrating how rare cannabinoids can help protect the brain.

Vancouver, BC-based InMed Pharmaceuticals (InMed) on Wednesday announced the filing of the application which demonstrates neuroprotection and enhanced neuronal function using a rare cannabinoid.

Potential neurodegenerative disease treatment applications include Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease.

Neurological Treatment Using Rare Cannabinoids

InMed says the Patent Cooperation Treaty (PCT), Compositions and Methods for Treating Neuronal Disorders with Cannabinoids, focuses on using a rare cannabinoid to inhibit or slow neurodegenerative diseases.

A PCT is an international patent law treaty that serves as a unified procedure for applying for patents, protecting inventions of member nations.

Currently, there are 153 countries in the PCT, including the United States, Japan, Canada, Australia, New Zealand, China, Brazil, Russia, and India.

The rare cannabinoid in InMed’s PCT application is new to the company’s portfolio.

According to InMed, the rare cannabinoid functions as a neuroprotectant in areas with affected neurons.

InMed says that the PCT application demonstrates that the subject cannabinoid compound can promote neurite outgrowth, demonstrating a potential to enhance neuronal function.

Encouraging Early Results

InMed Senior Vice President of Pre-Clinical Research & Development Dr. Eric Hsu says they are pleased with early results.

“We are very encouraged by this initial data demonstrating potential for the use of a rare cannabinoid to improve neuronal function and provide neuroprotection for treating neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease,” says Dr. Hsu. “This PCT patent application advances our strategy directed towards researching and developing rare cannabinoids as potential pharmaceutical therapeutics for diseases with high unmet medical needs. Expanding our patient portfolio to include, in addition to cannabinol (CBN), an incremental rare cannabinoid for the potential treatment of major neurodegeneration indications demonstrates our continued commitment to our pharmaceutical programs and the potential of rare cannabinoids in medicine.”

InMed says the new development enhances its patent portfolio.

According to InMed, its patent portfolio currently includes twelve patent families dealing with rare cannabinoids, seven of which focus on manufacturing technologies and five on products and formulations.

With the recent acquisition of BayMedica, InMed says it has expanded its patent portfolio further to include additional biosynthetic pathways and semi-synthetic production of natural, rare cannabinoids and cannabinoid analogs.

BayMedica focuses on developing an expanding library of new patentable cannabinoid analogs with an array of clinical applications.